BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ravagalimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ravagalimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06972446-5949@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ravagalimab: Phase 2 readout est. (NCT06972446)
DESCRIPTION:Ravagalimab\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study t
 o Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthr
 itis\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ravagalimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06972446
URL:https://assetmemo.bio/drug/ravagalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
